Evolution of the Patient's Perception of the Use of the Upper Limb After a Stroke During Intensive Rehabilitation (ValetM-2024)

April 8, 2026 updated by: Grand Hôpital de Charleroi
This study is being carried out in the context of rehabilitation after stroke, where persistent upper limb weakness is a major challenge. It aims to explore the relationship between observed function and patients' perceived participation in use.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Belgium
    • Hainaut
      • Charleroi, Hainaut, Belgium, 6060
        • Recruiting
        • Grand Hôpital de Charleroi
        • Contact:
      • Mons, Hainaut, Belgium, 7000

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients who have suffered a first stroke will be selected on transfer to a neurological rehabilitation service. They will be recruited on admission, provided they meet the inclusion and exclusion criteria.

A combination of self-administered questionnaires and functional assessments will be carried out on the first day of multidisciplinary management in the neurological rehabilitation department and after two months in hospital.

Description

Inclusion Criteria:

  • First stroke as defined by the World Health Organization.
  • Upper limb paresis with a NIHSS National Institutes of Health Stroke Scale score > or = 1/4 for upper limb motor function

Exclusion Criteria:

  • Life expectancy <12 months
  • Inability to understand French.
  • Pre-existing severe multiple disability affecting arm function.
  • Presence of pre-existing central neurological pathologies.
  • Mini-Mental State Examination < 21

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients suffering from motor impairment of the upper limbs following a stroke
Voluntary patients suffering from motor impairment of the upper limbs following a stroke
Diagnostic test: Functional assessments
  • Computer Adaptive Test for Fugl-Meyer (CAT-FM)
  • Action Research Arm Test (ARAT)
  • Measurement of Functional Independence
  • Star cancellation test
  • Stroke Impact Scale
  • ACTIVLIM (assesses the ability to perform activities of daily living requiring the use of the upper limbs)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To assess whether the perception of use of the impaired upper limb improves during intensive rehabilitation after a stroke.
Time Frame: Up to 2 months
various tests : computer adaptive test F-M, ARA test, MIF test, star concellation test, ACTIVLIM test
Up to 2 months
To compare the difference between perception and observed function of the upper limb during intensive multidisciplinary rehabilitation treatment.
Time Frame: Up to 2 months
various tests : computer adaptive test F-M, ARA test, MIF test, star concellation test, ACTIVLIM test
Up to 2 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Grand Hôpital de Charleroi

Investigators

  • Principal Investigator: Maxime Valet, MD, Grand Hôpital de Charleroi

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 11, 2024

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2027

Study Registration Dates

First Submitted

August 19, 2024

First Submitted That Met QC Criteria

August 21, 2024

First Posted (Actual)

August 26, 2024

Study Record Updates

Last Update Posted (Actual)

April 13, 2026

Last Update Submitted That Met QC Criteria

April 8, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Perception Valet M 2024

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe